U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07517510) titled 'HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).' on April 01.
Brief Summary: This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment of MPAL.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
Intervention:
DRUG: HVA
HVA regimen: Venetoclax: 100 mg on day 1, 200 mg on Day 2, 400 mg per day from Day 3 to Day 14; Azacitidine: 75 mg/m2 per day by subcutaneous injection from Day 1...